Fig. 5

Evaluation of Discriminatory Efficacy Using Selected lncRNAs and Their Combinations on Malignant Pulmonary Nodules (MPN) and Benign Pulmonary Nodules (BPN).(a-f)Depiction of the expression profiles of linc01125 (a), SP2-AS1 (b), MIR100HG (c), ZNRF3-AS1 (d), HNF1A-AS1 (e), and linc01160 (f) in plasma-derived Epexo from patients diagnosed with MPN and BPN. Corresponding ROC curves for these lncRNAs are displayed alongside the bar chart illustrating their expression levels. The statistical significance was determined using unpaired t-tests with Welch's correction. (g)ROC curves illustrating the diagnostic performance of the best combination with (red line) or without consideration of nodule size (blue line). (h)Precision-recall curve demonstrating the diagnostic accuracy of the best combination in conjunction with nodule size. (i)Subgroup ROC curves showcasing the effectiveness of the optimal diagnostic combination in distinguishing MLN patients from BLN controls, categorized based on nodule size (≤10mm and > 10mm).